What is ADB-Fubinaca?
ADB-Fubinaca was first identified in a synthetic cannabis blend seized in Japan in 2013, and there have been a few reports of its identification in synthetic cannabis blends in the United States, Europe, and Asia.1 It is the (S)-enantiomer of AB-FUBINACA and is primarily used as a substitute for AB-FUBINACA as a designer drug since AB-FUBINACA is relatively less available. How Does Adb-Fubinaca Affect the Human Body? Adb-Fubinaca Affect the Body? Although adb-fubinaca is a synthetic cannabinoid drug, it is not as highly charged as psychoactive cannabinoids such as THC. It shows similar pharmacokinetics to other synthetic cannabinoids, including low plasma levels with a half-life of two to three days. Adb-Fubinaca tends to have a hallucinogenic and/or euphoriant effect.
Adb-Fubinaca’s effects on the body
Adb-Fubinaca is a Schedule I controlled substance in the United States. Controlled substances in Schedule I must have a high potential for abuse and no accepted medical use. In contrast, Schedule II drugs are Schedule II if they have low potential for abuse and some accepted medical use. ADB-fubinaca effects interact with the neurotransmitter glutamate to produce a psychoactive and behavioral response and to produce some vomiting symptoms. During the first few hours of onset, only the (+)-isomer of ADB-FUBINACA was found to produce these symptoms, but these effects did not last long. Due to the psychoactive effects of ADB-FUBINACA, it has been noted that this substance may affect brain development and may have lasting effects on mental development.
- Availability: In Stock
- Packaging: Aluminum foil bag package done by expert
- Purity: 98.8%
- Origin: China
- Minimum order: 10 Grams
- Production Capacity: 100KG/WEEK
- Transportation: Delivery done by EMS, DHL, FEDEX, UPS, and TNT
The legality of ADB-FUBINACA
ADB-FUBINACA is illegal in the United States. The DEA lists it as a Schedule I controlled substance, which denotes the highest degree of perceived drug activity, with no accepted medical use and a high potential for abuse. The term Schedule I includes analogs and salts of any of the controlled substances in schedule I, as well as all chemicals similar to, but not exactly like, the scheduled substances that the DEA considers to have a high potential for abuse under the criteria in the Controlled Substances Act. As of October 2018, the drug was not specifically scheduled in Mexico, though several states in the US, such as New York and Michigan, prohibit the sale of ADB-FUBINACA for human use.
What Are The Effects Of Adb-Fubinaca?
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively.ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. Buy ADB-FUBINACA online from https://rcchemsupply.com/product/adb-fubinaca/ appears to be the product of rational drug design since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
ADB fubinaca for sale
ADB-FUBINACA has a high potential for abuse due to its quick onset and long duration of action, high potency, and a high threshold. This high potency and high threshold lead to a high risk of overdose for the individual who is dependent on synthetic cannabis. ADB-FUBINACA is also listed as an experimental drug in the category of “drugs with no currently accepted medical use in treatment in the United States” in the United States’ most recent United States Food and Drug Administration (FDA) product label. Adb-Fubinaca is also known as 17-ANB, 17-acetyl-5-fluoro-ADB, AB-FUBINACA, and 18-Io-FUBINACA. ADB-FUBINACA is being developed by Pharmaleads and has been recently approved by the Food and Drug Administration of the United States as a Schedule 1 controlled substance in April 2018.